Canada’s largest medical cannabis company by revenue and production is planning to make a “significant” splash in the near future on another point of entry in the U.S. market, one of the company’s executives said in an interview.
Aurora, based in Edmonton, Alberta, already has arms-length involvement in the United States through Australis Capital, a Las Vegas-based investment group it spun off a year ago.
In a conference call with investors a day after releasing its earnings, CEO Terry Booth said Aurora is “laser focused” on exploring opportunities in the U.S. involving CBD derived from hemp.
Aurora’s strategic partners and Australis “are helping us talk to some of the top companies in the world,” he said on the call.
Chair Michael Singer added, “We see the U.S. market as a tremendous opportunity. This is a key objective in fiscal 2020. We expect … that we will have a significant footprint in the U.S. in the coming quarters.”
Industry heavyweights Canopy Growth, Tilray and Cronos Group have already laid out plans to spend hundreds of millions of dollars.
Aurora Chief Corporate Officer Cam Battley said the Alberta company is not ruling out anything.
“What I do expect is within a very short period of time we’ll be entering into the U.S. with another point of entry, and a significant one,” Battley told Marijuana Business Daily in a phone interview.
“We’re learning what the strengths and weaknesses are of (multistate operators) and other business models, so we are definitely laser-focused, short term, on CBD derived from hemp, because that can be done now. It’s fully permissible now.
“We’re also looking at stuff that may be more complicated and may require for us to be clever along the lines of what Canopy did.”
Battley was referencing Smiths Falls, Ontario-based Canopy’s deal to acquire Acreage Holdings, a New York cannabis firm, if and when the United States legalizes marijuana production and sales nationwide.
Aurora also disclosed expectations for outdoor production.
The company plans to harvest its first outdoor crop in Canada in the coming week and is weighing outdoor production beyond Canada.
“We know we’re going to use outdoor grow as a piece of the puzzle in multiple parts of the world,” Battley told MJBizDaily.
The Canadian outdoor production will not be used for commercial sales and – for now – is intended to facilitate research into cultivation techniques.
Aurora says it is weeks away from adding two more European Union Good Manufacturing Practice (GMP) certifications in Canada.
EU-GMP certification – the accepted seal for international quality compliance – is key to accessing international medical cannabis markets through exports.
Aurora’s international sales have been hampered by a shortage of export-grade medical marijuana.
Global medical sales were only 4 million Canadian dollars ($3 million) in the previous quarter.
The two facilities – Aurora Vie in Pointe-Claire, Quebec, and Aurora River in Bradford – together have a production capacity of 32,000 kilograms (70,548 pounds) per year.
“EU-GMP is becoming an international standard, rightly, not just in the European Union, but elsewhere in the world,” Battley said. “That’s good for us as an industry. It’s good for us to have tight regulation. Regulation is a good thing. We should embrace it.”
Australis trades on the Canadian Securities Exchange as AUSA.
For analysis and in-depth looks at the investment trends and deals driving the cannabis industry forward, sign up for our premium subscription service, Investor Intelligence.